Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bernadett E Szabados"'
Autor:
Maud Rijnders, J. Alberto Nakauma-González, Debbie G. J. Robbrecht, Alberto Gil-Jimenez, Hayri E. Balcioglu, Astrid A. M. Oostvogels, Maureen J. B. Aarts, Joost L. Boormans, Paul Hamberg, Michiel S. van der Heijden, Bernadett E. Szabados, Geert J. L. H. van Leenders, Niven Mehra, Jens Voortman, Hans M. Westgeest, Ronald de Wit, Astrid A. M. van der Veldt, Reno Debets, Martijn P. Lolkema
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-13 (2024)
Abstract Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic urothelial cancer (mUC), but therapeutic success at the individual patient level varies significantly. Here we identify predictive markers of response, b
Externí odkaz:
https://doaj.org/article/5c826962a5fb45ffbb47fc08f0218098
Autor:
Vishal Navani, J Connor Wells, Devon J Boyne, Winson Y Cheung, Darren M Brenner, Bradley A McGregor, Chris Labaki, Andrew L Schmidt, Rana R McKay, Luis Meza, Sumanta K Pal, Frede Donskov, Benoit Beuselinck, Maxwell Otiato, Lisa Ludwig, Thomas Powles, Bernadett E Szabados, Toni K Choueiri, Daniel Y C Heng
BACKGROUND: There are limited data evaluating the activity of cabozantinib (CABO) as second line (2L) therapy post standard of care ipilimumab-nivolumab (IPI-NIVO) or immuno-oncology(IO)/vascular endothelial growth factor inhibitor (VEGFi) combinatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a9fd530a1f2f3ecd64cfa5d480f36f4
https://lirias.kuleuven.be/handle/20.500.12942/717579
https://lirias.kuleuven.be/handle/20.500.12942/717579
Autor:
Maud Rijnders, J. Alberto Nakauma-González, Debbie G.J. Robbrecht, Alberto Gil-Jimenez, Maureen J.B. Aarts, Joost L. Boormans, Paul Hamberg, Michiel S. van der Heijden, Bernadett E. Szabados, Geert J.L.H. van Leenders, Niven Mehra, Jens Voortman, Hans M. Westgeest, Ronald de Wit, Astrid A.M. van der Veldt, Reno Debets, Martijn P. Lolkema
Immune checkpoint inhibitors (ICIs) improve overall survival in patients with metastatic urothelial cancer (mUC). To identify predictive markers of response, whole-genome DNA (n=70) and RNA-sequencing (n=41) were performed using fresh metastatic biop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f689af0518876df1df616b1834adfd55
https://doi.org/10.1101/2022.05.30.493997
https://doi.org/10.1101/2022.05.30.493997